Synergistic effects of plasma S100B and MRI measures of cerebrovascular disease on cognition in older adults
- PMID: 39907937
- PMCID: PMC12181517
- DOI: 10.1007/s11357-024-01498-1
Synergistic effects of plasma S100B and MRI measures of cerebrovascular disease on cognition in older adults
Abstract
There is growing interest in studying vascular contributions to cognitive impairment and dementia (VCID) and developing biomarkers to identify at-risk individuals. A combination of biofluid and neuroimaging markers may better profile early stage VCID than individual measures. Here, we tested this possibility focusing on plasma levels of S100 calcium-binding protein B (S100B), which has been linked with blood-brain-barrier (BBB) integrity, and neuroimaging measures assessing BBB function (water exchange rate across the BBB (kw)) and cerebral small vessel disease (white matter hyperintensities (WMHs)). A total of 74 older adults without dementia had plasma samples collected and underwent cognitive assessment. A subsample had neuroimaging data including diffusion prepared pseudo-continuous arterial spin labeling (DP-pCASL) for assessment of BBB kw and T2-weighted fluid-attenuated inversion recovery (FLAIR) for quantification of WMHs. Results indicated that higher plasma S100B levels were associated with poorer episodic memory performance (β = - .031, SE = .008, p < .001). Moreover, significant interactions were observed between plasma S100B levels and parietal lobe BBB kw (interaction β = .095, SE = .042, p = .028) and between plasma S100B levels and deep WMH volume (interaction β = - .025, SE = .009, p = .007) for episodic memory. Individuals with the poorest memory performance showed both high plasma S100B and either low BBB kw in the parietal lobe or increased deep WMH burden. Taken together, our results provide support for the combined use of biofluid and neuroimaging markers in the study of VCID.
Keywords: Blood–brain barrier; Diffusion; Memory; S100B; Vascular contributions to cognitive impairment and dementia; White matter hyperintensities.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
Figures





Similar articles
-
MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols.Alzheimers Dement. 2021 Apr;17(4):716-725. doi: 10.1002/alz.12216. Epub 2021 Jan 21. Alzheimers Dement. 2021. PMID: 33480157 Free PMC article.
-
Heterogeneity and Penumbra of White Matter Hyperintensities in Small Vessel Diseases Determined by Quantitative MRI.Stroke. 2025 Jan;56(1):128-137. doi: 10.1161/STROKEAHA.124.047910. Epub 2024 Dec 9. Stroke. 2025. PMID: 39648904
-
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2. Cochrane Database Syst Rev. 2022. PMID: 35833913 Free PMC article.
-
Regional differences in the link between water exchange rate across the blood-brain barrier and cognitive performance in normal aging.Geroscience. 2024 Feb;46(1):265-282. doi: 10.1007/s11357-023-00930-2. Epub 2023 Sep 15. Geroscience. 2024. PMID: 37713089 Free PMC article.
-
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306. doi: 10.1002/14651858.CD013306.pub2. Cochrane Database Syst Rev. 2021. PMID: 33704781 Free PMC article.
References
-
- Corriveau RA, Bosetti F, Emr M, Gladman JT, Koenig JI, Moy CS, et al. The science of vascular contributions to cognitive impairment and dementia (VCID): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol Neurobiol. 2016;36(2):281–8. 10.1007/s10571-016-0334-7. - PMC - PubMed
-
- Zlokovic BV, Gottesman RF, Bernstein KE, Seshadri S, McKee A, Snyder H, et al. Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimer’s Dement. 2020;16(12):1714–33. 10.1002/alz.12157. - PubMed
MeSH terms
Substances
Grants and funding
- P30 AG072946/AG/NIA NIH HHS/United States
- UL1TR001998/TR/NCATS NIH HHS/United States
- P01 AG078116/AG/NIA NIH HHS/United States
- R01 AG068055/AG/NIA NIH HHS/United States
- R01 AG055449/AG/NIA NIH HHS/United States
- R01 NS134712/NS/NINDS NIH HHS/United States
- U01 NS100614/NS/NINDS NIH HHS/United States
- UL1 TR001998/TR/NCATS NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- RF1 AG084072/AG/NIA NIH HHS/United States
- R01 AG075583/AG/NIA NIH HHS/United States
- RF1 NS122028/NS/NINDS NIH HHS/United States
- R01 NS133250/NS/NINDS NIH HHS/United States
- NIA P30 AG028383/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous